Outcomes of limited-stage DLBCL according to prognostic risk models
| Outcomes according to stage-modified IPI . | |||||
|---|---|---|---|---|---|
| Study design . | Population . | Treatment . | sm-IPI, n (%) . | Outcomes . | |
| Prospective studies | |||||
| Randomized phase 3 SWOG 8736, Miller (1998)32 | N = 401 | CHOP x3 + RT or CHOP x8 | 0-1 = 289 (72) 2 = 82 (20) 3 = 28 (7) 4 = 2 (<1) | 5-y PFS 0-1 = 77% 2 = 60% 3 = 34% | 5-y OS 0-1 = 82% 2 = 71% 3 = 48% |
| Prospective single-arm SWOG 0014, Persky (2008)33 | N = 60; sm-IPI ≥ 1; age > 60 | R-CHOP x3 + RT | 0 = 0 (0) 1 = 42 (70) 2 = 12 (20) 3 = 6 (10) 4 = 0 (0) | 2-y PFS 1 = 100%> 1 = 78% | |
| Prospective PET-adapted SWOG S1001, Persky et al (2019)11 | N = 132 (128 evaluable) | R-CHOP x3 Then PET− 1 x R-CHOP or PET+: RT + ibritumomab tiuxetan | 0 = 35 (27)1 = 55 (42)2 = 37 (28)3 = 5 (4) | 5-y PFS 0 = 97% 1/2 = 86% 3 = 30% | |
| Retrospective studies | |||||
| Retrospective single-center, Kumar et al (2015)24 | N = 261 (194 evaluable) | R-CHOP x3-6 +/− RT | 0 = 48 (25) 1 = 83 (43) 2 = 42 (21) 3 = 21 (11) | 5-y PFS 0 = 95.3% 1 = 87.7% 2 = 83.4% 3 = 61.9% | 5-y OS 0 = 100%, 1 = 95.2% 2 = 85.8% 3 = 74.2% |
| Retrospective multicenter, Barraclough et al (2019)19 | N = 201 (171 evaluable) | R-CHOP +/− RT | 0-1 = 93 (55) 2 = 45 (26) 3-4 = 33 (19) | 4-y OS 0-1 = 95% 2 = 86% 3-4 = 67% | |
| Retrospective multicenter, Mian et al (2014)34 | N = 1405 (254 evaluable for mIPI) | R-CHOP +/− RT | 0-1 = 127 (50) 2 = 78 (31) 3-4 = 49 (19) | 5-y OS 75% (whole cohort) HR (95% CI) 0-1 = 1.00 2 = 6.04 (2.2-16.5) 3-4 = 9.08 (3.3-25) | |
| Outcomes according to stage-modified IPI . | |||||
|---|---|---|---|---|---|
| Study design . | Population . | Treatment . | sm-IPI, n (%) . | Outcomes . | |
| Prospective studies | |||||
| Randomized phase 3 SWOG 8736, Miller (1998)32 | N = 401 | CHOP x3 + RT or CHOP x8 | 0-1 = 289 (72) 2 = 82 (20) 3 = 28 (7) 4 = 2 (<1) | 5-y PFS 0-1 = 77% 2 = 60% 3 = 34% | 5-y OS 0-1 = 82% 2 = 71% 3 = 48% |
| Prospective single-arm SWOG 0014, Persky (2008)33 | N = 60; sm-IPI ≥ 1; age > 60 | R-CHOP x3 + RT | 0 = 0 (0) 1 = 42 (70) 2 = 12 (20) 3 = 6 (10) 4 = 0 (0) | 2-y PFS 1 = 100%> 1 = 78% | |
| Prospective PET-adapted SWOG S1001, Persky et al (2019)11 | N = 132 (128 evaluable) | R-CHOP x3 Then PET− 1 x R-CHOP or PET+: RT + ibritumomab tiuxetan | 0 = 35 (27)1 = 55 (42)2 = 37 (28)3 = 5 (4) | 5-y PFS 0 = 97% 1/2 = 86% 3 = 30% | |
| Retrospective studies | |||||
| Retrospective single-center, Kumar et al (2015)24 | N = 261 (194 evaluable) | R-CHOP x3-6 +/− RT | 0 = 48 (25) 1 = 83 (43) 2 = 42 (21) 3 = 21 (11) | 5-y PFS 0 = 95.3% 1 = 87.7% 2 = 83.4% 3 = 61.9% | 5-y OS 0 = 100%, 1 = 95.2% 2 = 85.8% 3 = 74.2% |
| Retrospective multicenter, Barraclough et al (2019)19 | N = 201 (171 evaluable) | R-CHOP +/− RT | 0-1 = 93 (55) 2 = 45 (26) 3-4 = 33 (19) | 4-y OS 0-1 = 95% 2 = 86% 3-4 = 67% | |
| Retrospective multicenter, Mian et al (2014)34 | N = 1405 (254 evaluable for mIPI) | R-CHOP +/− RT | 0-1 = 127 (50) 2 = 78 (31) 3-4 = 49 (19) | 5-y OS 75% (whole cohort) HR (95% CI) 0-1 = 1.00 2 = 6.04 (2.2-16.5) 3-4 = 9.08 (3.3-25) | |
| Outcomes according to NCCN-IPI . | |||||
|---|---|---|---|---|---|
| Study design . | Population . | Treatment . | NCCN-IPI, n (%) . | Outcomes . | |
| Retrospective studies | |||||
| Retrospective multicenter Mian et al (2014)34 | N = 1405 (234 evaluable for NCCN-IPI) | (R)-CHOP +/− RT | 0-1 = 88 (38) 2-3 = 119 (51) 4-6 = 27 (11) | 5-y OS 0-1 = 98% 2-3 = 82% 4-6 = 57% | |
| Outcomes according to NCCN-IPI . | |||||
|---|---|---|---|---|---|
| Study design . | Population . | Treatment . | NCCN-IPI, n (%) . | Outcomes . | |
| Retrospective studies | |||||
| Retrospective multicenter Mian et al (2014)34 | N = 1405 (234 evaluable for NCCN-IPI) | (R)-CHOP +/− RT | 0-1 = 88 (38) 2-3 = 119 (51) 4-6 = 27 (11) | 5-y OS 0-1 = 98% 2-3 = 82% 4-6 = 57% | |
sm-IPI factors are elevated LDH, age > 60, nonbulky stage II, ECOG 2.
CI, confidence interval; HR, hazards ratio; NCCN-IPI, national comprehensive cancer network international prognostic index; PFS, progression free survival; R-CHOP, rituximab, cyclophosphamide, doxorubicin, vincristine, prednisolone.